{
  "meta": {
    "title": "Heart_Failure_Cardiomyopathies",
    "url": "https://brainandscalpel.vercel.app/heart-failure-cardiomyopathies-82471bb0.html",
    "scrapedAt": "2025-11-29T18:24:39.941Z"
  },
  "questions": [
    {
      "id": 6607,
      "choices": [
        {
          "id": 26397,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add digoxin </span></span></span></p>"
        },
        {
          "id": 26398,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
        },
        {
          "id": 26399,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol dosage </span></span></span></p>"
        },
        {
          "id": 26400,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch lisinopril to valsartan-sacubitril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 67-year-old woman with stable heart failure with reduced ejection fraction (HFrEF) is on maximum doses of lisinopril, among other medications. Which treatment is most appropriate to further reduce HF hospitalizations and mortality?</span></span></span></p>",
      "unique_key": "Q1413244",
      "question_audio": null,
      "question_video": null,
      "map_id": 19669,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Switch lisinopril to valsartan-sacubitril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril has been shown to significantly reduce mortality and HF hospitalizations in patients with HFrEF compared to ACE inhibitors or ARBs alone. This makes it a preferred treatment option for patients who are already on maximum doses of these medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> While it can reduce HF hospitalizations, it does not improve mortality. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used for patients with HFrEF in sinus rhythm and a high heart rate despite beta-blocker therapy. Not applicable here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increasing carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Might not be tolerated well and has not shown the same mortality benefit as valsartan-sacubitril.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril significantly reduces heart failure hospitalizations and mortality in patients with symptomatic heart failure with reduced ejection fraction and is recommended in preference to an ACE inhibitor or angiotensin receptor blocker.</span></span></span></p>",
      "correct_choice_id": 26400,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6608,
      "choices": [
        {
          "id": 26401,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 26402,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing </span></span></span></p>"
        },
        {
          "id": 26403,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
        },
        {
          "id": 26404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lisinopril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old athlete experiences cardiac arrest during a race and is successfully resuscitated. Resting ECG is shown. Echocardiogram shows normal LV function but RV dilation and dysfunction. What is the most appropriate management before discharge?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-115610.jpg\" style=\"height:207px; width:500px\" /></span></span></p>",
      "unique_key": "Q2742687",
      "question_audio": null,
      "question_video": null,
      "map_id": 19670,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Implantable cardioverter-defibrillator (ICD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sudden cardiac arrest with &lsquo;&epsilon;&rsquo; wave in ECG and RV dysfunction in echo in young athletes raises suspicion for underlying inherited cardiomyopathies, like arrhythmogenic right ventricular cardiomyopathy (ARVC). An ICD is the most appropriate intervention to prevent sudden cardiac death due to arrhythmias. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone:</span></strong><span style=\"font-size:12.0pt\"> Antiarrhythmic medication, but not as effective as ICD for preventing sudden death. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Genetic testing:</span></strong><span style=\"font-size:12.0pt\"> Important for diagnosis and family screening, but not the immediate priority before discharge.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lisinopril:</span></strong><span style=\"font-size:12.0pt\"> ACE inhibitor for LV dysfunction, not indicated in this case with normal LV function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with sustained ventricular arrhythmias (&gt;30 seconds) or cardiac arrest without a reversible cause have a class 1 recommendation for secondary prevention with implantable cardioverter-defibrillator placement.</span></span></span></p>",
      "correct_choice_id": 26403,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6609,
      "choices": [
        {
          "id": 26405,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac MRI </span></span></p>"
        },
        {
          "id": 26406,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exercise echocardiography </span></span></p>"
        },
        {
          "id": 26407,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right and left heart catheterization </span></span></p>"
        },
        {
          "id": 26408,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum &alpha;-galactosidase level</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with ascites, pedal edema and elevated JVP. ECG showed low voltage complexes and echo showed increased LV wall thickness. He also has a history of carpal tunnel syndrome. What is the most appropriate test?</span></span></p>",
      "unique_key": "Q2768512",
      "question_audio": null,
      "question_video": null,
      "map_id": 19671,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Cardiac MRI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of heart failure, increased wall thickness, low voltage on ECG, and carpal tunnel syndrome raises suspicion for infiltrative cardiomyopathy, like transthyretin amyloid (ATTR) amyloidosis. CMR with gadolinium is the most sensitive and specific test for diagnosing cardiac amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise echocardiography:</span></strong><span style=\"font-size:12.0pt\"> Primarily used to diagnose coronary artery disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Right and left heart catheterization:</span></strong><span style=\"font-size:12.0pt\"> Invasive and not the first-line test for infiltrative cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum &alpha;-galactosidase level:</span></strong><span style=\"font-size:12.0pt\"> Used to diagnose Fabry disease, which usually causes Hypertrophic Cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac magnetic resonance imaging with gadolinium is highly sensitive and specific for cardiac amyloidosis, but it does not distinguish between AL (immunoglobulin light-chain) amyloidosis and transthyretin amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with cardiac magnetic resonance imaging findings consistent with cardiac amyloidosis, an abnormal 99m-technetium pyrophosphate scan would confirm transthyretin amyloidosis without the need for a biopsy.</span></span></p>",
      "correct_choice_id": 26405,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6610,
      "choices": [
        {
          "id": 26409,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
        },
        {
          "id": 26410,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin (SGLT2 inhibitor) </span></span></span></p>"
        },
        {
          "id": 26411,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Furosemide </span></span></span></p>"
        },
        {
          "id": 26412,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivabradine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man with heart failure with mildly reduced ejection fraction (HFmrEF) and type 2 diabetes mellitus is asymptomatic and on appropriate medications. Which additional treatment is most appropriate?</span></span></p>",
      "unique_key": "Q7322336",
      "question_audio": null,
      "question_video": null,
      "map_id": 19672,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Empagliflozin (SGLT2 inhibitor)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular death and HF hospitalizations in patients with type 2 diabetes and HF, regardless of the ejection fraction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> Reduces HF hospitalizations but not mortality, and this patient is asymptomatic. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Furosemide:</span></strong><span style=\"font-size:12.0pt\"> Loop diuretic, indicated for volume overload which is not present in this patient.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used for HF with reduced ejection fraction (HFrEF) with high heart rates despite beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A sodium-glucose cotransporter 2 inhibitor is recommended to reduce risk for worsening heart failure and cardiovascular death in patients with type 2 diabetes mellitus and established heart failure with reduced ejection fraction</span></span></p>",
      "correct_choice_id": 26410,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6611,
      "choices": [
        {
          "id": 26413,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute pulmonary embolism</span></span></span></p>"
        },
        {
          "id": 26414,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascending aortic dissection </span></span></span></p>"
        },
        {
          "id": 26415,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy </span></span></span></p>"
        },
        {
          "id": 26416,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 8-day postpartum woman presents with acute heart failure symptoms. Echocardiogram shows LV dilation and hypokinesis with an ejection fraction of 38%.RV is normal. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8366476",
      "question_audio": null,
      "question_video": null,
      "map_id": 19673,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Peripartum cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy is characterized by the development of heart failure in the last month of pregnancy or within 5 months postpartum. The presentation of LV dysfunction with no other identifiable cause fits this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute pulmonary embolism</span></strong><span style=\"font-size:12.0pt\">: Less likely given normal right heart function on echocardiogram. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Ascending aortic dissection:</strong> Usually presents with acute chest pain, and echo would show aortic abnormalities. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Spontaneous coronary artery dissection:</strong> Typically presents with chest pain and ECG changes indicative of ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripartum cardiomyopathy is left ventricular systolic dysfunction with onset toward the end of pregnancy or in the months after delivery in the absence of another identifiable cause; patients often present with features of heart failure.</span></span></p>",
      "correct_choice_id": 26415,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6612,
      "choices": [
        {
          "id": 26417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous milrinone </span></span></span></p>"
        },
        {
          "id": 26418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous nitroglycerin </span></span></span></p>"
        },
        {
          "id": 26419,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase furosemide </span></span></span></p>"
        },
        {
          "id": 26420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start CVVH (Continuous venovenous hemofiltration)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old man with decompensated heart failure is hospitalized and treated with a maximal dose of IV furosemide. He has minimal urine output and persistent signs of volume overload. What is the most appropriate next step?</span></span></span></p>",
      "unique_key": "Q2512177",
      "question_audio": null,
      "question_video": null,
      "map_id": 19674,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Start CVVH (Continuous venovenous hemofiltration)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute decompensated heart failure (ADHF) who are unresponsive to maximal diuretic therapy (as evidenced by minimal urine output and persistent volume overload), the next step is to initiate ultrafiltration. CVVH is a form of renal replacement therapy that gently removes excess fluid over a longer period, making it well-suited for patients who may not tolerate the rapid fluid shifts of hemodialysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Add intravenous milrinone:</span></strong><span style=\"font-size:12.0pt\"> Milrinone is an inotrope used to improve cardiac contractility. While it may help with cardiac output, it doesn&#39;t directly address the volume overload and can worsen renal function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add intravenous nitroglycerin:</span></strong><span style=\"font-size:12.0pt\"> Nitroglycerin is a vasodilator that can reduce preload and afterload, but it&#39;s not the primary treatment for volume overload when diuretics fail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase furosemide:</span></strong><span style=\"font-size:12.0pt\"> The patient is already on the maximal dose of furosemide, so further increases would not be effective and could lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with ADHF who are unresponsive to maximal diuretic therapy, CVVH is a crucial intervention to manage volume overload and prevent further complications.</span></span></p>",
      "correct_choice_id": 26420,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6613,
      "choices": [
        {
          "id": 26421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
        },
        {
          "id": 26422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation </span></span></span></p>"
        },
        {
          "id": 26423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular assist device (LVAD) placement </span></span></span></p>"
        },
        {
          "id": 26424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with ischemic cardiomyopathy (EF 20%) is on maximally tolerated heart failure medications and experiencing significant functional decline. He wishes to pursue care that will restore functionality. What is the most appropriate long-term treatment?</span></span></p>",
      "unique_key": "Q9379264",
      "question_audio": null,
      "question_video": null,
      "map_id": 19675,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Heart transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation is the most appropriate long-term treatment for patients with advanced heart failure who have persistent severe symptoms despite optimal medical therapy. It can significantly improve quality of life and survival in suitable candidates. This patient&#39;s young age (56 years old) and desire for functional improvement make him a potential candidate for transplantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> Although it can reduce hospitalizations, it does not improve survival or functional capacity. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LVAD placement:</span></strong><span style=\"font-size:12.0pt\"> LVADs are a bridge to transplantation or destination therapy for those who are not transplant candidates. This patient may be eligible for transplant. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tolvaptan:</span></strong><span style=\"font-size:12.0pt\"> Used for hyponatremia, but not a primary treatment for advanced heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with persistent severe heart failure symptoms despite maximal medical therapy are candidates for advanced treatment; acceptable candidates for cardiac transplantation are generally younger than 65 to 70 years with no medical contraindications and have good social support and adherence.</span></span></p>",
      "correct_choice_id": 26422,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6614,
      "choices": [
        {
          "id": 26425,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add eplerenone</span></span></span></p>"
        },
        {
          "id": 26426,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
        },
        {
          "id": 26427,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch carvedilol to metoprolol succinate </span></span></span></p>"
        },
        {
          "id": 26428,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch losartan to valsartan-sacubitril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old man with a history of HFrEF and AF, presents for follow-up with stable NYHA class III symptoms. He is currently on losartan, carvedilol, empagliflozin, furosemide, and apixaban. He has a history of ACE inhibitor-induced angioedema and spironolactone-induced gynecomastia. Which medication is the most appropriate addition to his current regimen?</span></span></p>",
      "unique_key": "Q3070788",
      "question_audio": null,
      "question_video": null,
      "map_id": 19676,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Add eplerenone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone, a selective aldosterone antagonist, is indicated in patients with symptomatic HFrEF and normal kidney function to improve survival. This patient has normal renal function and has not tolerated spironolactone due to gynecomastia. Eplerenone is a suitable alternative as it has a lower risk of endocrine side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Not indicated in patients with atrial fibrillation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Switch carvedilol to metoprolol succinate:</span></strong><span style=\"font-size:12.0pt\"> Not necessary, as there is no evidence of <strong>benefit in switching between beta-blockers in this scenario. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Switch losartan to valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> Contraindicated due to the history of ACE inhibitor-induced angioedema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone antagonist therapy (spironolactone, eplerenone) is indicated in all patients with symptomatic heart failure with reduced ejection fraction and normal kidney function to improve survival.</span></span></span></p>",
      "correct_choice_id": 26425,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6615,
      "choices": [
        {
          "id": 26429,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of valsartan-sacubitril </span></span></span></p>"
        },
        {
          "id": 26430,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) therapy </span></span></span></p>"
        },
        {
          "id": 26431,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Replacement of metoprolol with carvedilol </span></span></span></p>"
        },
        {
          "id": 26432,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy (SRT)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old man with hypertrophic cardiomyopathy (HCM) diagnosed at age 38 presents with exertional dyspnea. He is on metoprolol and disopyramide. Echocardiogram shows asymmetric septal hypertrophy, systolic anterior motion of the mitral valve (SAM), and a resting LVOT gradient of 64 mmHg. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q8465237",
      "question_audio": null,
      "question_video": null,
      "map_id": 19677,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Septal reduction therapy (SRT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SRT is indicated for patients with symptomatic HCM and an LVOT gradient &ge;50 mmHg despite optimal medical therapy. This patient&#39;s symptoms and high LVOT gradient warrant consideration for SRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> This medication is contraindicated in HCM due to the risk of worsening LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. ICD therapy:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in high-risk HCM patients but not the primary treatment for symptoms. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Replacement of metoprolol with carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Unlikely to be beneficial as both are beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy is indicated for symptomatic HCM patients with a significant LVOT gradient despite optimal medical therapy.</span></span></span></p>",
      "correct_choice_id": 26432,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6616,
      "choices": [
        {
          "id": 26433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascending aortic dissection </span></span></span></p>"
        },
        {
          "id": 26434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery dissection </span></span></span></p>"
        },
        {
          "id": 26435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery embolism </span></span></span></p>"
        },
        {
          "id": 26436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takotsubo cardiomyopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 76-year-old woman presents with acute substernal chest discomfort and dyspnea after seeing her dog being attacked and killed by another dog. Her echocardiogram shows apical and mid-ventricular hypokinesis with preserved basal function, and coronary angiography is normal. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4638172",
      "question_audio": null,
      "question_video": null,
      "map_id": 19678,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Takotsubo cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takotsubo cardiomyopathy, also called stress-induced cardiomyopathy, mimics acute coronary syndrome (ACS) with chest pain, dyspnea, and elevated cardiac biomarkers. However, it occurs without obstructive coronary artery disease and typically presents with apical ballooning on echocardiography. Emotional stress is a common trigger.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. &nbsp;Ascending aortic dissection:</span></strong><span style=\"font-size:12.0pt\"> This would typically present with severe tearing chest pain radiating to the back. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Coronary artery dissection:</span></strong><span style=\"font-size:12.0pt\"> This would show abnormalities on angiography. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Coronary artery embolism:</span></strong><span style=\"font-size:12.0pt\"> This would also cause regional wall motion abnormalities on echocardiogram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Takotsubo cardiomyopathy is a syndrome characterized by transient regional systolic ventricular dysfunction mimicking myocardial infarction in the absence of angiographic evidence of obstructive coronary artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of takotsubo cardiomyopathy is similar to that for heart failure of other causes; most patients recover cardiac function over several months.</span></span></p>",
      "correct_choice_id": 26436,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6617,
      "choices": [
        {
          "id": 26437,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac resynchronization therapy (CRT)</span></span></span></p>"
        },
        {
          "id": 26438,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac transplantation </span></span></span></p>"
        },
        {
          "id": 26439,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
        },
        {
          "id": 26440,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary vein isolation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with restrictive cardiomyopathy and atrial fibrillation presents with refractory heart failure symptoms despite optimal medical therapy. Echo shows an EF of 50%, severe biatrial enlargement and pulmonary hypertension. What is the most appropriate management?</span></span></span></p>",
      "unique_key": "Q2773853",
      "question_audio": null,
      "question_video": null,
      "map_id": 19679,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Cardiac transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation is an effective therapy for select patients with end-stage restrictive cardiomyopathy who have refractory symptoms despite optimal medical therapy. This patient&#39;s clinical presentation and echocardiographic findings suggest a poor prognosis, making him a potential candidate for transplantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. CRT:</span></strong><span style=\"font-size:12.0pt\"> Not indicated in patients with preserved EF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. ICD:</span></strong><span style=\"font-size:12.0pt\"> Not indicated for primary prevention in a patient with preserved EF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Pulmonary vein isolation:</span></strong><span style=\"font-size:12.0pt\"> May not be effective in patients with severe atrial enlargement and underlying restrictive cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Heart transplantation is an effective therapy for select patients with end-stage restrictive cardiomyopathy.</span></span></span></p>",
      "correct_choice_id": 26438,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6618,
      "choices": [
        {
          "id": 26441,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bisoprolol</span></span></span></p>"
        },
        {
          "id": 26442,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diltiazem </span></span></span></p>"
        },
        {
          "id": 26443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Enalapril </span></span></span></p>"
        },
        {
          "id": 26444,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivabradine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 27-year-old woman, 6 days postpartum, presents with acute heart failure symptoms (orthopnea, paroxysmal nocturnal dyspnea, elevated JVP, S3, crackles, edema). Echocardiogram shows an ejection fraction (EF) of 20% and diffuse hypokinesis. She is currently on furosemide and bilevel positive airway pressure (BiPAP). What is the most appropriate additional treatment?</span></span></span></p>",
      "unique_key": "Q2718510",
      "question_audio": null,
      "question_video": null,
      "map_id": 19680,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Enalapril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with peripartum cardiomyopathy (PPCM), a form of heart failure with reduced ejection fraction (HFrEF). ACE inhibitors like enalapril are the cornerstone of HFrEF treatment and have been shown to reduce morbidity and mortality. They can be safely used in breastfeeding women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Bisoprolol (beta-blocker):</span></strong><span style=\"font-size:12.0pt\"> While beneficial in HFrEF, it should be initiated cautiously after volume status is optimized in acute decompensated heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Diltiazem (non-dihydropyridine calcium channel blocker):</span></strong><span style=\"font-size:12.0pt\"> Contraindicated in HFrEF due to negative inotropic effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used in HFrEF patients with sinus rhythm and elevated heart rate despite optimal beta-blocker therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACE inhibitors reduce morbidity and mortality in patients with heart failure with reduced ejection fraction and should be used in both symptomatic and asymptomatic patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol, carvedilol, and bisoprolol reduce mortality in patients with heart failure with reduced ejection fraction, but treatment should be delayed in patients with volume overload until the patient is closer to being euvolemic.</span></span></p>",
      "correct_choice_id": 26443,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6619,
      "choices": [
        {
          "id": 26445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Athlete&#39;s heart </span></span></span></p>"
        },
        {
          "id": 26446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fabry disease </span></span></span></p>"
        },
        {
          "id": 26447,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertensive heart disease </span></span></span></p>"
        },
        {
          "id": 26448,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nonobstructive hypertrophic cardiomyopathy (HCM)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old man with no prior medical history undergoes a pre-participation sports examination. ECG shows sinus bradycardia and voltage criteria for left ventricular (LV) hypertrophy. Echocardiogram shows mild LV dilation and symmetric LV hypertrophy with a normal LV ejection fraction and diastolic function. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8327083",
      "question_audio": null,
      "question_video": null,
      "map_id": 19681,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Athlete&#39;s heart</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Athlete&#39;s heart is a benign condition characterized by physiological cardiac remodeling in response to intense exercise. The ECG findings of sinus bradycardia and LV hypertrophy are common in athletes. Echocardiogram may also show mild LV dilation and increased wall thickness, but diastolic function remains normal, differentiating it from pathological conditions like HCM. Also, hypertrophy in the athlete&rsquo;s heart regresses with cessation of training and is accompanied by <em><u>supernormal exercise capacity</u></em> (VO2max &gt;50 mL/kg per min). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fabry disease:</span></strong><span style=\"font-size:12.0pt\"> A lysosomal storage disorder that can cause LV hypertrophy but is also associated with other systemic manifestations like angiokeratomas and renal dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Hypertensive heart disease:</span></strong><span style=\"font-size:12.0pt\"> Usually occurs in older individuals with a history of hypertension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Nonobstructive HCM:</span></strong><span style=\"font-size:12.0pt\"> A genetic disorder that causes asymmetric LV hypertrophy and often has impaired diastolic function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased left ventricular (LV) wall thickness and LV cavity dilatation may be normal findings in highly trained athletes; symmetric wall thickness of 13 mm or less and normal diastolic filling favor the diagnosis of athlete heart over the diagnosis of HCM.</span></span></span></p>",
      "correct_choice_id": 26445,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6620,
      "choices": [
        {
          "id": 26449,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac resynchronization therapy-defibrillator (CRT-D) </span></span></span></p>"
        },
        {
          "id": 26450,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
        },
        {
          "id": 26451,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable pulmonary artery pressure sensor </span></span></span></p>"
        },
        {
          "id": 26452,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wearable cardioverter-defibrillator</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 63-year-old man who is a known case of HFrEF presents with persistent NYHA III symptoms despite optimal medical therapy. ECG shows LBBB and echo shows an EF of 25%. What is the most appropriate treatment?</span></span></span></p>",
      "unique_key": "Q1009068",
      "question_audio": null,
      "question_video": null,
      "map_id": 19682,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Cardiac resynchronization therapy-defibrillator (CRT-D)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRT-D is indicated in patients with HFrEF (EF &le; 35%), LBBB with QRS duration &ge; 150 ms (or 120-149 ms in some cases), and NYHA class II-IV symptoms despite optimal medical therapy. CRT improves symptoms and survival, and the defibrillator component provides protection against sudden cardiac death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. ICD:</span></strong><span style=\"font-size:12.0pt\"> May be indicated for primary prevention of sudden cardiac death but doesn&#39;t address the LBBB and dyssynchrony. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Implantable pulmonary artery pressure sensor:</span></strong><span style=\"font-size:12.0pt\"> Used for monitoring, not for treating heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Wearable cardioverter-defibrillator:</span></strong><span style=\"font-size:12.0pt\"> Temporary measure, not appropriate for long-term management of heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac resynchronization therapy is indicated in patients with New York Heart Association functional class II to IV symptoms despite guideline-directed medical therapy who have an ejection fraction of 35% or less, sinus rhythm, and left bundle branch block with a QRS duration of 150 ms or longer.</span></span></p>",
      "correct_choice_id": 26449,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6621,
      "choices": [
        {
          "id": 26453,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart failure with preserved ejection fraction (HFpEF) </span></span></span></p>"
        },
        {
          "id": 26454,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-output heart failure </span></span></span></p>"
        },
        {
          "id": 26455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HOCM </span></span></span></p>"
        },
        {
          "id": 26456,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HFrEF</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old woman with hypertension and paroxysmal AF presents with a 6-month history of exertional dyspnea. She has normal vital signs, clear lungs, and a normal JVP. Echocardiography shows an ejection fraction of 55%, increased left ventricular wall thickness, and an enlarged left atrium. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q3454055",
      "question_audio": null,
      "question_video": null,
      "map_id": 19683,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Heart failure with preserved ejection fraction (HFpEF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HFpEF is characterized by symptoms of heart failure, preserved ejection fraction, and evidence of diastolic dysfunction (increased LV wall thickness and LA enlargement). This patient&#39;s presentation and echocardiographic findings are consistent with HFpEF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. High-output heart failure:</span></strong><span style=\"font-size:12.0pt\"> This is associated with an elevated cardiac index, which is not present in this case. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. HOCM:</span></strong><span style=\"font-size:12.0pt\"> This would show LV outflow tract obstruction, which is absent in this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. HFrEF:</span></strong><span style=\"font-size:12.0pt\"> Unlikley given the normal EF in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">HFpEF should be suspected in patients who meet the following three criteria: symptoms of heart failure, left ventricular ejection fraction of 50% or greater, and no other apparent cause of HF symptoms.</span></span></span></p>",
      "correct_choice_id": 26453,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7078,
      "choices": [
        {
          "id": 28280,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Disopyramide </span></span></span></p>"
        },
        {
          "id": 28281,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
        },
        {
          "id": 28282,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy </span></span></span></p>"
        },
        {
          "id": 28283,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with hypertrophic cardiomyopathy (HCM) experiences an episode of syncope and was admitted. 2D Echo revealed a maximum LV wall thickness of 30 mm and a dynamic LVOT obstruction. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q8344771",
      "question_audio": null,
      "question_video": null,
      "map_id": 19684,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Implantable cardioverter-defibrillator (ICD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Risk factors include SCD judged definitively or likely attributable to HCM in one or more first-degree or close relatives aged 50 years or younger, left ventricular (LV) hypertrophy of 30 mm or greater in any LV segment, one or more recent episodes of syncope suspected by clinical history to be arrhythmic in nature, LV apical aneurysm, and LV ejection fraction less than 50%. Based on the patient&#39;s recent episode of unexplained syncope and LV wall thickness of 30 mm, it is reasonable to refer her for consideration of an ICD to prevent SCD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Disopyramide:</span></strong><span style=\"font-size:12.0pt\"> Primarily used for treating HF symptoms in HCM (in case if &beta;B or CCB therapy is ineffective) </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. &nbsp;Septal reduction therapy:</span></strong><span style=\"font-size:12.0pt\"> Indicated for symptomatic patients with significant LVOT obstruction, but not for primary prevention of SCD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Verapamil:</span></strong><span style=\"font-size:12.0pt\"> Used for symptom relief in HCM, but not for SCD prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider ICD therapy for primary prevention of SCD in patients with HCM and high-risk features. </span></span></p>",
      "correct_choice_id": 28281,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7079,
      "choices": [
        {
          "id": 28284,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplant </span></span></span></p>"
        },
        {
          "id": 28285,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECMO </span></span></span></p>"
        },
        {
          "id": 28286,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular assist device (LVAD) placement </span></span></span></p>"
        },
        {
          "id": 28287,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add H-ISDN</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 74-year-old man presents with progressive fatigue, dyspnea and edema. He has a history of ischemic cardiomyopathy with an EF of 10% and had 4 hospitalizations in the last 6 months. He is currently on sacubitril-valsartan, carvedilol, eplerenone, furosemide and empagliflozin. Labs reveal a S. creatinine of 1.7 mg/dL and S. Na of&nbsp; 128 mEq/L. What is the most reasonable next step in management?</span></span></span></p>",
      "unique_key": "Q7504181",
      "question_audio": null,
      "question_video": null,
      "map_id": 19685,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Left ventricular assist device (LVAD) placement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has advanced heart failure with a very low ejection fraction, multiple comorbidities, and intolerance to standard medical therapy. He is not a suitable candidate for heart transplantation due to his age and comorbidities. LVAD placement is a reasonable option to improve his symptoms, quality of life, and potentially bridge him to transplantation if he becomes eligible in the future.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Heart transplant:</span></strong> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This patient is not a candidate for heart transplant based on his age and recent colon cancer. Most centers have an age cutoff of 65 years (but variable). With the exception of skin cancer, most programs require that a patient be cancer-free for at least 5 years before being considered for heart transplant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Ecmo:</span></strong><span style=\"font-size:12.0pt\"> Ecmo is a short-term life support option and is not suitable for long-term management of heart failure. it is typically reserved for refractory acute heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C.&nbsp; Add H-ISDN:</span></strong><span style=\"font-size:12.0pt\"> Adding another medication would not be expected to provide significant benefit in this case of severe heart failure with maximized GDMT. Typically, H-ISDN is used for patients who are not able to tolerate ARNi/ACEi and ARB. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Left ventricular assist devices, either as a bridge to heart transplant or as primary therapy, are reasonable in patients with advanced heart failure.</span></span></span></p>",
      "correct_choice_id": 28286,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7080,
      "choices": [
        {
          "id": 28288,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular (AV) node ablation with permanent pacemaker implantation</span></span></span></p>"
        },
        {
          "id": 28289,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) placement </span></span></span></p>"
        },
        {
          "id": 28290,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left atrial appendage occlusion (LAAO)</span></span></span></p>"
        },
        {
          "id": 28291,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rhythm control</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old woman with paroxysmal AF and HFrEF (EF 45%) has recurrent hospitalizations due to acute heart failure. She is currently on apixaban, metoprolol, furosemide, and telmisartan. What is the most appropriate treatment?</span></span></span></p>",
      "unique_key": "Q8695744",
      "question_audio": null,
      "question_video": null,
      "map_id": 19686,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Rhythm control</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aggressive rhythm control (with antiarrhythmic drugs or catheter ablation) has been shown to reduce morbidity and mortality in patients with HF and AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with HFrEF, recent clinical trials have shown that catheter ablation of AF is associated with a favorable effect on morbidity and mortality compared with medical therapy. Amiodarone is another option for rhythm control. Although amiodarone carries a risk for toxicity, this patient&#39;s lifetime exposure to the drug is likely to be relatively low given her age, comorbid conditions, and probable amiodarone dosage, which is generally lower for AF than for ventricular arrhythmias. Monitored appropriately, it can be used safely and effectively in patients her age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. AV node ablation:</span></strong><span style=\"font-size:12.0pt\"> Considered only if rate and rhythm control fails to control tachycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ICD:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in certain patients, but not the primary treatment for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LAAO:</span></strong><span style=\"font-size:12.0pt\"> Used for stroke prevention in patients who have C/I for anticoagulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aggressive efforts to achieve rhythm control in patients with atrial fibrillation and concomitant heart failure decrease morbidity and mortality.</span></span></p>",
      "correct_choice_id": 28291,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7082,
      "choices": [
        {
          "id": 28296,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
        },
        {
          "id": 28297,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Glimepiride </span></span></span></p>"
        },
        {
          "id": 28298,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Dapagliflozin </span></span></span></p>"
        },
        {
          "id": 28299,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Saxagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old woman with ischemic cardiomyopathy (EF 38%) and type 2 diabetes mellitus has well-controlled blood pressure and glycemic control. She is on aspirin, atorvastatin, valsartan-sacubitril, metoprolol succinate, and metformin. Her BNP. What is the most appropriate additional treatment?</span></span></p>",
      "unique_key": "Q6480713",
      "question_audio": null,
      "question_video": null,
      "map_id": 19687,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors have been shown to reduce cardiovascular death and heart failure hospitalization in patients with HFrEF, regardless of diabetes status. They also slow the progression of diabetic kidney disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glimepiride (sulfonylurea):</span></strong><span style=\"font-size:12.0pt\"> No proven cardiovascular benefit. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide:</span></strong><span style=\"font-size:12.0pt\"> Shown to reduce CV events in T2DM but not specifically in HFrEF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Saxagliptin:</span></strong><span style=\"font-size:12.0pt\"> Not recommended in HFrEF due to the potential for increased hospitalizations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors in patients with HFrEF, even if their diabetes is well-controlled, to reduce CV morbidity and mortality.</span></span></span></p>",
      "correct_choice_id": 28298,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7083,
      "choices": [
        {
          "id": 28300,
          "text": "<p><span style=\"font-size:12.0pt;\">Aortic stenosis</span></p>"
        },
        {
          "id": 28301,
          "text": "<p><span style=\"font-size:12.0pt;\">Cardiac tamponade</span></p>"
        },
        {
          "id": 28302,
          "text": "<p><span style=\"font-size:12.0pt;\">Heart failure with reduced ejection fraction</span></p>"
        },
        {
          "id": 28303,
          "text": "<p><span style=\"font-size:12.0pt;\">Large pericardial effusion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 69-year-old woman is evaluated in the emergency department for a 1-week history of progressive exertional dyspnea and orthopnea. Vital signs are normal. Focused point-of-care cardiac ultrasonography is performed and done and as shown below. Which of the following is the most likely&nbsp;diagnosis?</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/supawork-e53ff9bb04dd417abdf7b818ed4326bc.gif\" width=\"600\" height=\"406\"></p>",
      "unique_key": "Q4189323",
      "question_audio": null,
      "question_video": null,
      "map_id": 19688,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Heart failure with reduced ejection fraction</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Heart failure with reduced ejection fraction (HFrEF) is characterized by a reduced left ventricular ejection fraction (LVEF), typically &lt;40%, as seen in the ultrasonographic findings. Symptoms such as progressive exertional dyspnea and orthopnea are hallmark clinical manifestations of left-sided heart failure, commonly due to impaired myocardial contractility.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Aortic stenosis</strong>: Aortic stenosis typically presents with symptoms such as chest pain, syncope, and heart failure. However, the ultrasound findings do not suggest aortic valve pathology or significant left ventricular outflow obstruction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Cardiac tamponade</strong>: Cardiac tamponade would present with findings such as hypotension, jugular venous distension, and pulsus paradoxus. The ultrasound in tamponade typically shows a large pericardial effusion with diastolic collapse of the right atrium or right ventricle. These findings are not present in this case.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Large pericardial effusion</strong>: A large pericardial effusion would show a significant fluid accumulation around the heart on ultrasound, often leading to tamponade physiology. This is not observed in the provided ultrasound image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Recognize the clinical presentation of heart failure with reduced ejection fraction (HFrEF) and correlate it with echocardiographic findings, emphasizing the importance of identifying left ventricular systolic dysfunction in patients presenting with symptoms of heart failure.</span></p>",
      "correct_choice_id": 28302,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7087,
      "choices": [
        {
          "id": 28316,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Cardiac tamponade</span></span></span></p>"
        },
        {
          "id": 28317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Eosinophilic pneumonia</span></span></span></p>"
        },
        {
          "id": 28318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphangioleiomyomatosis</span></span></span></p>"
        },
        {
          "id": 28319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary edema</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man is evaluated in the emergency department for acute worsening of dyspnea. Chest radiograph is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-115748.jpg\" style=\"height:370px; width:400px\" /></span></span></p>",
      "unique_key": "Q4234359",
      "question_audio": null,
      "question_video": null,
      "map_id": 19689,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Pulmonary edema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s chest radiograph shows cardiomegaly and bilateral perihilar alveolar infiltrates, consistent with a diagnosis of pulmonary edema due to heart failure. A small left pleural effusion is seen, as well as fluid in the minor fissure, also consistent with heart failure. Although cardiomegaly can be seen in tamponade, diffuse alveolar infiltrates are not a feature of this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cardiac tamponade</span></strong><span style=\"font-size:12.0pt\">: While cardiomegaly can be seen in cardiac tamponade, which is a condition where fluid accumulates in the sac surrounding the heart, leading to compression of the heart, diffuse alveolar infiltrates are not a feature of cardiac tamponade. Therefore, this diagnosis is unlikely based on the radiographic findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eosinophilic pneumonia</span></strong><span style=\"font-size:12.0pt\">: Eosinophilic pneumonia is characterized by the presence of eosinophils (a type of white blood cell) in the lung tissue, which typically presents with bilateral infiltrates on a chest radiograph. However, this condition does not usually present with cardiomegaly or pleural effusion, making this option less likely given the findings on the radiograph.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Lymphangioleiomyomatosis:</strong> Lymphangioleiomyomatosis is a rare lung disease that affects the lungs and lymphatic system, leading to cystic lung disease. The chest radiograph for this condition would typically show diffuse thin-walled cysts rather than cardiomegaly, alveolar infiltrates, or pleural effusion. Thus, this diagnosis is inconsistent with the radiographic findings in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary edema is characterized by cardiomegaly and bilateral perihilar alveolar infiltrates on a chest radiograph, often associated with pleural effusion and fluid in the minor fissure, especially in the context of heart failure. This is a key diagnostic feature that must be remembered.</span></span></span></p>",
      "correct_choice_id": 28319,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7088,
      "choices": [
        {
          "id": 28320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage A </span></span></span></p>"
        },
        {
          "id": 28321,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage B </span></span></span></p>"
        },
        {
          "id": 28322,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage C </span></span></span></p>"
        },
        {
          "id": 28323,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage D</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with a past medical history of coronary artery disease develops a myocardial infarction. He got treated in CCU and before he is discharged, he undergoes echocardiography, which reveals a left ventricular ejection fraction of 35% to 40%. He is asymptomatic. Repeat Echo after 3 months shows the same findings. What is this patient&rsquo;s heart failure stage?</span></span></span></p>",
      "unique_key": "Q6574719",
      "question_audio": null,
      "question_video": null,
      "map_id": 19690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Stage B</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has structural heart disease (reduced ejection fraction due to prior myocardial infarction) but no current symptoms of heart failure. This places him in <strong>Stage B</strong> heart failure according to the American College of Cardiology/American Heart Association (ACC/AHA) classification.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stage A:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage A have risk factors for HF but no structural heart disease or symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stage C:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage C have structural heart disease and current or prior symptoms of HF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stage D:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage D have refractory HF requiring specialized interventions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACC/AHA staging system for heart failure, categorizes patients based on the presence or absence of structural heart disease and symptoms of heart failure. </span></span></p>",
      "correct_choice_id": 28321,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7090,
      "choices": [
        {
          "id": 28328,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis </span></span></span></p>"
        },
        {
          "id": 28329,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fabry disease </span></span></span></p>"
        },
        {
          "id": 28330,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dilated Cardiomyopathy </span></span></span></p>"
        },
        {
          "id": 28331,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrictive cardiomyopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old woman with a history of recurrent heart failure hospitalizations presents with ascites and edema. Her JVP was elevated and there was no change with inspiration. On examination, she has an audible low-pitched late diastolic sound with a pansystolic murmur in the left sternal border. Echo shows diastolic dysfunction with mildly increased LV wall thickness. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2519408",
      "question_audio": null,
      "question_video": null,
      "map_id": 19691,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Restrictive cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ascites and edema:</span></strong><span style=\"font-size:12.0pt\"> These are signs of right heart failure, which can be a consequence of RCM due to increased left atrial pressure.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated JVP with no inspiratory decline:</span></strong><span style=\"font-size:12.0pt\"> This finding, known as Kussmaul&#39;s sign, is suggestive of impaired right ventricular filling, seen in RCM and constrictive pericarditis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Low-pitched late diastolic sound (S4):</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark of RCM and indicates diastolic dysfunction/ stiff ventricle. Patients can have S3 as well. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pansystolic murmur at the left sternal border:</span></strong><span style=\"font-size:12.0pt\"> This suggests tricuspid regurgitation, a common complication of RCM due to right ventricular dilatation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Echo findings:</span></strong><span style=\"font-size:12.0pt\"> Diastolic dysfunction with mildly increased LV wall thickness is typical of RCM.</span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Constrictive pericarditis:</span></strong><span style=\"font-size:12.0pt\"> While this can also cause elevated JVP and diastolic dysfunction, it usually does not present with a pansystolic murmur or S3 gallop. Pericardial knock is more characteristic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fabry disease:</span></strong><span style=\"font-size:12.0pt\"> This is a rare genetic disorder that can cause RCM, but it is less likely than other causes in this patient without a specific family history or other suggestive features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dilated cardiomyopathy:</span></strong><span style=\"font-size:12.0pt\"> This presents with systolic dysfunction (reduced ejection fraction) and a dilated left ventricle, which are not seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive cardiomyopathy presents with features of right heart failure, Kussmaul&#39;s sign, S3/S4 gallop, diastolic dysfunction, and associated findings like TR.</span></span></p>",
      "correct_choice_id": 28331,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7113,
      "choices": [
        {
          "id": 28420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of valsartan-sacubitril</span></span></span></p>"
        },
        {
          "id": 28421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) therapy </span></span></span></p>"
        },
        {
          "id": 28422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Replacement of metoprolol with carvedilol </span></span></span></p>"
        },
        {
          "id": 28423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy (SRT)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with a history HF and HCM presents with NYHA class III dyspnea. She is currently on metoprolol and disopyramide. Echocardiogram shows an EF of 78% and LVOT gradient of 64 mmHg at rest. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q6750054",
      "question_audio": null,
      "question_video": null,
      "map_id": 19692,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Septal reduction therapy (SRT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SRT is indicated for patients with symptomatic HCM and an LVOT gradient&ge; 50 mm Hg despite optimal medical therapy. This patient&#39;s symptoms and high LVOT gradient warrant consideration for SRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> Contraindicated in HCM as it can worsen LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. &nbsp;ICD:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in high-risk HCM patients, but not for symptomatic relief of LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Replacing metoprolol with carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Unlikely to be beneficial, as both are beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Septal reduction therapy is the treatment of choice for symptomatic patients with HCM and a high LVOT gradient despite optimal medical therapy.</span></span></p>",
      "correct_choice_id": 28423,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7114,
      "choices": [
        {
          "id": 28424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sacubitril-Valsartan </span></span></span></p>"
        },
        {
          "id": 28425,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
        },
        {
          "id": 28426,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spironolactone </span></span></span></p>"
        },
        {
          "id": 28427,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man presents with dyspnea on exertion. His resting ECG is normal. 2D echo revealed diastolic dysfunction, mild concentric LVH, and an LV EF of 65%. His BNP levels were elevated. Which of the following will maximally increase survival in this patient?</span></span></p>",
      "unique_key": "Q1391346",
      "question_audio": null,
      "question_video": null,
      "map_id": 19693,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) None of the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with heart failure with preserved ejection fraction (HFpEF). Currently, there are no medications proven to significantly reduce mortality in HFpEF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The medications listed (Sacubitril-Valsartan, Empagliflozin, Spironolactone) are primarily used for heart failure with reduced ejection fraction (HFrEF), where they have shown mortality benefits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Sacubitril-Valsartan:</span></strong><span style=\"font-size:12.0pt\"> This is an angiotensin receptor-neprilysin inhibitor (ARNI) indicated for HFrEF, not HFpEF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Empagliflozin:</span></strong><span style=\"font-size:12.0pt\"> This is an SGLT2 inhibitor shown to benefit patients with HFrEF and may reduce hospitalizations in HFpEF, but not proven to improve survival. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Spironolactone:</span></strong><span style=\"font-size:12.0pt\"> While this mineralocorticoid receptor antagonist may improve symptoms and reduce hospitalizations in HFpEF, it has not been shown to reduce mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">There are no medications currently proven to significantly improve survival in HFpEF. Management primarily focuses on symptom management. </span></span></span></p>",
      "correct_choice_id": 28427,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7115,
      "choices": [
        {
          "id": 28428,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amyloidosis </span></span></span></p>"
        },
        {
          "id": 28429,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcoidosis </span></span></span></p>"
        },
        {
          "id": 28430,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocarditis </span></span></span></p>"
        },
        {
          "id": 28431,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic heart disease (IHD)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Circumferential subendocardial late-gadolinium enhancement (LGE) is seen in?</span></span></p>",
      "unique_key": "Q5395916",
      "question_audio": null,
      "question_video": null,
      "map_id": 19694,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Amyloidosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Late gadolinium enhancement (LGE) on cardiac MRI is a technique used to visualize areas of myocardial fibrosis or scarring. Circumferential subendocardial LGE is a characteristic pattern seen in cardiac amyloidosis. The abnormal protein deposits in amyloidosis lead to diffuse subendocardial fibrosis, resulting in this pattern on LGE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/untitled-2.jpg\" style=\"height:480px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Sarcoidosis typically shows a patchy or focal pattern of LGE, often in the mid-myocardial or subepicardial layers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Myocarditis:</span></strong><span style=\"font-size:12.0pt\"> Myocarditis can have various patterns of LGE, including patchy, focal, or epicardial, depending on the extent and distribution of inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ischemic heart disease (IHD):</span></strong><span style=\"font-size:12.0pt\"> IHD typically shows subendocardial or transmural LGE in a coronary artery distribution, corresponding to areas of infarction or ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Circumferential subendocardial late-gadolinium enhancement (LGE) on cardiac MRI is a hallmark feature of cardiac amyloidosis.</span></span></p>",
      "correct_choice_id": 28428,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7116,
      "choices": [
        {
          "id": 28432,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class I </span></span></span></p>"
        },
        {
          "id": 28433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II </span></span></span></p>"
        },
        {
          "id": 28434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class III </span></span></span></p>"
        },
        {
          "id": 28435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proportion of sudden cardiac death (SCD) in heart failure is maximum among which of the following NYHA classes?</span></span></p>",
      "unique_key": "Q8331222",
      "question_audio": null,
      "question_video": null,
      "map_id": 19695,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Class II</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While more severe heart failure (HF) is associated with a higher overall mortality rate and a higher absolute rate of SCD, the proportion of deaths attributed to SCD actually decreases as HF severity increases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This trend is highlighted in the MERIT-HF trial:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class II: 6.3% risk of SCD at one year (64% of total deaths)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class III: 10.5% risk of SCD at one year (59% of total deaths)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class IV: 18.6% risk of SCD at one year (33% of total deaths)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This data indicates that while the absolute number of SCD cases is higher in more severe HF, other causes of death become more prominent as HF progresses. Therefore, the highest proportion of deaths due to SCD occurs in NYHA Class II.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proportion of deaths due to SCD is highest in NYHA Class II.</span></span></span></p>",
      "correct_choice_id": 28433,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7118,
      "choices": [
        {
          "id": 28440,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium channels </span></span></span></p>"
        },
        {
          "id": 28441,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmosomal proteins </span></span></span></p>"
        },
        {
          "id": 28442,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sodium channels</span></span></span></p>"
        },
        {
          "id": 28443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcomere proteins </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ms. Kalavathy, a 35-year-old Anglo-Indian from Ireland, experienced cardiac arrest due to monomorphic VT with a LBBB morphology. Coronary angiogram and echocardiogram were normal. Echo is shown. Which protein mutation is most likely responsible for her presentation?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-124018.jpg\" style=\"height:106px; width:700px\" /></span></span></span></p>",
      "unique_key": "Q9707186",
      "question_audio": null,
      "question_video": null,
      "map_id": 19696,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Desmosomal proteins</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation (young age, cardiac arrest due to VT, with LBBB morphology, normal coronary arteries and LV function, T-wave inversions in V1-V3 with epsilon wave) is highly suggestive of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is most commonly caused by mutations in genes encoding desmosomal proteins, which are responsible for cell-to-cell adhesion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Potassium channels:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these channels cause long QT syndrome, characterized by a prolonged QT interval on ECG and syncope.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Sodium channel:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these channels cause Brugada syndrome, characterized by a specific ECG pattern and increased risk of sudden cardiac death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><strong><span style=\"font-size:12.0pt\">. Sarcomere proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these proteins cause hypertrophic cardiomyopathy, which would show LV hypertrophy on echocardiogram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ARVC is a rare genetic disorder most commonly due to mutations in genes encoding cardiac desmosomal proteins. Approximately 50% have a familial transmission&nbsp;</span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with autosomal dominant inheritance.</span></span></p>",
      "correct_choice_id": 28441,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7121,
      "choices": [
        {
          "id": 28452,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class I </span></span></span></p>"
        },
        {
          "id": 28453,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II </span></span></span></p>"
        },
        {
          "id": 28454,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class III </span></span></span></p>"
        },
        {
          "id": 28455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with a history of MI and HF is comfortable at rest. However, when walking to his car, he develops dyspnea, fatigue, and sometimes palpitations. He must rest for several minutes before these symptoms resolve. Which of the following is his NYHA classification?</span></span></span></p>",
      "unique_key": "Q4923981",
      "question_audio": null,
      "question_video": null,
      "map_id": 19697,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Class III</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The New York Heart Association (NYHA) classification is a system used to categorize the severity of heart failure based on the patient&#39;s functional capacity and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Class III:</span></strong><span style=\"font-size:12.0pt\"> Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient in this case experiences symptoms with mild exertion (walking to his car) but is comfortable at rest, indicating a marked limitation of activity. Therefore, he falls into <strong>NYHA Class III</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Class I:</span></strong><span style=\"font-size:12.0pt\"> No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath), or angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Class II:</span></strong><span style=\"font-size:12.0pt\"> Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Class IV:</span></strong><span style=\"font-size:12.0pt\"> Unable to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the NYHA classification, Class III heart failure is defined by marked limitation of physical activity where patients are comfortable at rest, but less than ordinary activity (e.g., walking short distances) causes symptoms such as dyspnea, fatigue, and palpitations.</span></span></p>",
      "correct_choice_id": 28454,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7123,
      "choices": [
        {
          "id": 28460,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Confusion </span></span></span></p>"
        },
        {
          "id": 28461,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early hunger </span></span></span></p>"
        },
        {
          "id": 28462,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nocturia without polyuria </span></span></span></p>"
        },
        {
          "id": 28463,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right upper quadrant pain</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a symptom of heart failure?</span></span></p>",
      "unique_key": "Q9913607",
      "question_audio": null,
      "question_video": null,
      "map_id": 19698,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Early hunger</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early satiety (not early hunger) is a symptom of heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Confusion:</span></strong><span style=\"font-size:12.0pt\"> This can occur in HF, particularly in older adults or those with severe HF. It is often due to decreased cerebral perfusion caused by reduced cardiac output.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nocturia without polyuria:</span></strong><span style=\"font-size:12.0pt\"> This is a common symptom of HF, especially in the early stages. It is caused by redistribution of fluid from the legs to the central circulation when lying down.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Right upper quadrant pain:</span></strong><span style=\"font-size:12.0pt\"> This can be caused by liver congestion due to right heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize the various symptoms of heart failure.</span></span></span></p>",
      "correct_choice_id": 28461,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53495,
      "choices": [
        {
          "id": 213461,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced maternal age</span></span></span></p>"
        },
        {
          "id": 213462,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malnutrition</span></span></span></p>"
        },
        {
          "id": 213463,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primiparous</span></span></span></p>"
        },
        {
          "id": 213464,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Twin pregnancy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are a risk factor for development of peripartum cardiomyopathy EXCEPT:</span></span></span></p>",
      "unique_key": "Q7405820",
      "question_audio": null,
      "question_video": null,
      "map_id": 25278,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Primiparous</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy is a rare complication of pregnancy and can occur during the last trimester or within the first 6 months postpartum. Risk factors include advanced age, increased parity, twin pregnancy, malnutrition, use of tocolytic therapy and preeclampsia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Advanced maternal age:</strong> Advanced maternal age is a recognized risk factor for peripartum cardiomyopathy due to the increased cardiovascular strain and the higher likelihood of pre-existing heart conditions in older pregnant women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Malnutrition:</strong> Malnutrition is another risk factor because inadequate nutrition can impair the heart muscle&#39;s ability to function properly, thereby increasing the risk of developing cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Twin pregnancy:</strong> A twin pregnancy significantly increases the workload on the heart, making it a well-documented risk factor for peripartum cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primiparous status (first pregnancy) is not a risk factor for peripartum cardiomyopathy, whereas advanced maternal age, malnutrition, and twin pregnancy are significant risk factors for the development of this condition.</span></span></p>",
      "correct_choice_id": 213463,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53497,
      "choices": [
        {
          "id": 213469,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ibuprofen</span></span></span></p>"
        },
        {
          "id": 213470,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ramipril</span></span></span></p>"
        },
        {
          "id": 213471,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oseltamivir</span></span></span></p>"
        },
        {
          "id": 213472,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You admit a 19-year-old with acute HF and LV dysfunction. After assessment, you suspect acute viral myocarditis, which is confirmed on endomyocardial biopsy. Which of the following therapies is recommended for treatment for acute viral myocarditis?</span></span></span></p>",
      "unique_key": "Q6735971",
      "question_audio": null,
      "question_video": null,
      "map_id": 25279,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ramipril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Currently, no specific therapy is recommended for viral myocarditis at any stage. Anti-inflammatory or immunosuppressive medications are avoided during acute infection, as they may increase viral replication and myocardial injury. The use of antiviral agents, like oseltamivir, for cardiac involvement has not been studied. Research is ongoing into antiviral therapy for chronic viral persistence identified through endomyocardial biopsy. Large trials for immunosuppressive therapy in Dallas Criteria&ndash;positive myocarditis have shown negative results, though there are some initial promising findings for immune-mediated myocarditis. However, neither antiviral nor anti-inflammatory therapies are currently recommended. Until further understanding is gained, treatment follows general guidelines for dilated cardiomyopathy, including ACE inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ibuprofen:</span></strong><span style=\"font-size:12.0pt\"> Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID). Although it is commonly used to reduce inflammation and pain, its use is generally avoided in viral myocarditis. This is because NSAIDs can potentially increase the risk of adverse outcomes by inhibiting prostaglandin synthesis, which is essential for maintaining renal function and controlling inflammatory responses. Furthermore, NSAIDs might increase viral replication, leading to worsening of the condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oseltamivir:</span></strong><span style=\"font-size:12.0pt\"> Oseltamivir is an antiviral medication primarily used to treat influenza. It is not effective for treating viral myocarditis because it specifically targets the influenza virus and has not been studied for cardiac involvement. Therefore, it is not recommended for the treatment of viral myocarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> Prednisone is a corticosteroid with potent anti-inflammatory effects. However, the use of immunosuppressive therapies, including corticosteroids like prednisone, is generally avoided in the acute phase of viral myocarditis because they may increase the risk of viral replication and myocardial injury. Current evidence does not support the use of prednisone in acute viral myocarditis, and large trials have shown negative results in treating myocarditis with immunosuppressive therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of acute viral myocarditis, Ramipril (an ACE inhibitor) is recommended to manage heart failure symptoms and improve cardiac function, while anti-inflammatory, immunosuppressive, and specific antiviral therapies are generally not recommended.</span></span></p>",
      "correct_choice_id": 213470,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}